CN Patent

CN102886045A — 治疗吉非替尼耐药性癌症的方法

Assigned to Wyeth LLC · Expires 2013-01-23 · 13y expired

What this patent protects

本发明涉及治疗吉非替尼和/或埃罗替尼耐药性癌症的方法。在用吉非替尼和/或埃罗替尼治疗后监测癌症患者的癌症发展。癌症的发展指示癌症对吉非替尼和/或埃罗替尼耐药。一旦表明癌症在发展，则给予患者含不可逆性表皮生长因子受体(EGFR)抑制剂的药用组合物。在优选的实施方案中，不可逆性EGFR抑制剂是EKB-569、HKI-272和HKI-357。

USPTO Abstract

本发明涉及治疗吉非替尼和/或埃罗替尼耐药性癌症的方法。在用吉非替尼和/或埃罗替尼治疗后监测癌症患者的癌症发展。癌症的发展指示癌症对吉非替尼和/或埃罗替尼耐药。一旦表明癌症在发展，则给予患者含不可逆性表皮生长因子受体(EGFR)抑制剂的药用组合物。在优选的实施方案中，不可逆性EGFR抑制剂是EKB-569、HKI-272和HKI-357。

Drugs covered by this patent

Patent Metadata

Patent number
CN102886045A
Jurisdiction
CN
Classification
—
Expires
2013-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.